Copyright
©The Author(s) 2019.
World J Gastroenterol. Aug 21, 2019; 25(31): 4555-4566
Published online Aug 21, 2019. doi: 10.3748/wjg.v25.i31.4555
Published online Aug 21, 2019. doi: 10.3748/wjg.v25.i31.4555
Table 1 Study and patient characteristics of the included studies
Ref. | Year of publication | Country | Study design | Founding sources | Patient spectrum | Inclusion criteria | Disease activity | No. of patients | Age, yr, mean (range)or mean ± SD | Gender, male: female |
Del Vescovo et al[19] | 2008 | Italy | Prospective | NR | Known CD/healthy controls | Proven terminal ileum CD/no history of bowel disease | 8 active CD, 8 non-active CD, 7 healthy controls | 23 | 37.5 ± 17.41 | 15:8 |
Grieser et al[18] | 2012 | Germany | Retrospective | NR | Known CD | Referred to MRI for evaluation of disease activity | 24 active CD, 24 patients non-active CD | 48 | 37 ± 11 | 16:32 |
Koh et al[10] | 2001 | England | Prospective | NR | Known CD | Clinically symptoma-tic patients referred to MRI by gastroenterologists | 23 active CD, 7 patients non-active CD | 30 | 37.6 (18-58) | 14:16 |
Quaia et al[17] | 2014 | Italy | Retrospective | NR | Known CD | Clinically symptoma-tic patients referred to MRI for evaluation of disease activity | 47 active CD, 44 patients non-active CD | 91 | 39.6 ± 17.1 | 47:44 |
Zappa et al[11] | 2011 | France | Retrospective | NR | Known CD | Patients who were to undergo bowel resection for small bowel CD | 42 active CD, 11 patients non-active CD | 53 | 35 (15-74) | 28:25 |
Table 2 Index test and reference standard characteristics of the included studies
Ref. | Vendor (Model) | Magnetstrength, T | Technique | Bowelpreparation | Luminal contrast | Spasmolytic agent | Intravenous contrast | MRI sequences | Postcontrast sequence timing | Index test readers (Years of experience) | Reference standard | Interval1 |
Del Vescovo et al[19] | Siemens Corp. (Magnetom Symphony) | 1.5 | EG | NR | 1.2-2 L PEG solution orally 45 min prior | Buscopan 20 mg iv | 0.1 mmol/kg Gadodiamide (Omniscan) | T2-HASTE, True-FISP, T1-FLASH fs (pre/postcontrast) | 15 s, 60 s, 100 s, 160 s, 220 s, 280 s, 340 s, 400 s, 460 s | 2 blinded radiologists in consensus (NR) | Endoscopy with biopsy | NR |
Grieser et al[18] | GE Healthcare (Twin Speed) | 1.5 | EC | 8 hrs fasting | 1-2 L water, 80 mL/min, 20 min prior; 30 mL/min during MRI | Buscopan 10 mg iv | 0.2 mL/kg Gd-DTPA (Magnevist) | SSFP, FIESTA, FRFSE, T1-SPGR fs (pre/postcontrast) | 60-70 s | 2 blinded radiologists in consensus (6,12) | Endoscopy with biopsy and/or surgery | Endoscopy ≤ 3 d; surgery ≤ 10 d |
Koh et al[10] | Siemens Corp. (Magnetom Impact) | 1 | EG | NR | 600 mL water orally 30 min prior | Buscopan 1 mg im | 0.1 mmol/kg Gadodiamide (Omniscan) | T2-TSE, T1-FLASH, T1-FLASH fs (pre/postcontrast) | 20 s | 2 blinded radiologists in consensus (NR) | Endoscopy with biopsy and/or surgery | Median 21 d |
Quaia et al[17] | Philips (Achieva) | 1.5 | EG | 8 hrs fasting | 2 L PEG solution orally 60 min prior and diatrizoate meglumine and diatrizoate sodium solution rectally | Buscopan 40 mg iv | 0.2 mL/kg Gadobenate dimeglumine (Multihance) | T2-HASTE, T2-SPAIR, T1-FISP, T1-THRIVE 3D fs (pre/postcontrast) | 30 s, 70 s, 3 min, 5 min | 2 blinded radiologists in consensus (10,12) | Endoscopy with biopsy or surgery | ≤ 30 d |
Zappa et al[11] | Philips (Intera) | 1.5 | EG | NR | 1 L mannitol solution orally | Glucagon 1 mg iv | 0.2 mL/kg Gadoterate meglumine (Dotarem) | T2-SSH-TSE fs, True-FISP, T1-FLASH 3D (pre/postcontrast) | 90 s, 8 min | 2 blinded radiologists in consensus (NR) | Surgery | ≤ 90 d (mean 24 d, range 1–90 d, median 14 d) |
Table 3 Two-by-two data of the included studies
- Citation: Bellini D, Rivosecchi F, Panvini N, Rengo M, Caruso D, Carbone I, Ferrari R, Paolantonio P, Laghi A. Layered enhancement at magnetic resonance enterography in inflammatory bowel disease: A meta-analysis. World J Gastroenterol 2019; 25(31): 4555-4566
- URL: https://www.wjgnet.com/1007-9327/full/v25/i31/4555.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i31.4555